Asunercept
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Asunercept
- Accession Number
- DB15160
- Description
Asunercept is under investigation in clinical trial NCT02853565 (A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme).
- Type
- Biotech
- Groups
- Investigational
- Synonyms
- Asunercept
- External IDs
- APG101
Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset- Indication
- Not Available
- Contraindications & Blackbox Warnings
Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Asunercept. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Asunercept. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Asunercept. Alirocumab The risk or severity of adverse effects can be increased when Alirocumab is combined with Asunercept. Ansuvimab The risk or severity of adverse effects can be increased when Asunercept is combined with Ansuvimab. Anthrax immune globulin human The risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Asunercept. Antilymphocyte immunoglobulin (horse) The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Asunercept. Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Asunercept. Asfotase alfa The risk or severity of adverse effects can be increased when Asfotase alfa is combined with Asunercept. Atezolizumab The risk or severity of adverse effects can be increased when Atezolizumab is combined with Asunercept. 
Improve patient outcomesBuild effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.Learn more - Food Interactions
- Not Available
Categories
- Drug Categories
- Amino Acids, Peptides, and Proteins
- Antibodies
- Blood Proteins
- Glioma, drug therapy
- Globulins
- Immunoglobulin Isotypes
- Immunoglobulins
- Immunoproteins
- Membrane Proteins
- Proteins
- Receptors, Cell Surface
- Receptors, Cytokine
- Receptors, Death Domain
- Receptors, Immunologic
- Receptors, Tumor Necrosis Factor
- Recombinant Proteins
- Serum Globulins
- Classification
- Not classified
Chemical Identifiers
- UNII
- F333OQQ9UV
- CAS number
- 1450882-18-4
References
- General References
- Not Available
- External Links
- Wikipedia
- Asunercept
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Glioblastoma Multiforme (GBM) 1 2 Recruiting Treatment Coronavirus Disease 2019 (COVID‑19) / COVID-19 Induced Pneumonia 1 1 Completed Treatment Glioblastoma Multiforme (GBM) 1 1 Completed Treatment Myelodysplastic Syndrome 1 1, 2 Recruiting Treatment Glioblastoma, Adult 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created on May 20, 2019 14:54 / Updated on February 21, 2021 18:55